You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapse-Remitting Multiple Sclerosis (RR-MS)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis, Relapsing-Remitting, Adult ALL, Vitamin D3 Deficiency Trial (25(OH)D3, vitamin D3)

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • +2 more
  • 25(OH)D3
  • vitamin D3
  • (no location specified)
Apr 16, 2022

Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in United

Recruiting
  • Relapsing Multiple Sclerosis
  • +2 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • Best Available Therapy (BAT)
  • Palo Alto, California
  • +20 more
Jan 25, 2023

Multiple Sclerosis Trial in Italy, Poland, United States (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Loma Linda, California
  • +22 more
Jan 13, 2023

Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)

Recruiting
  • Relapse Remitting Multiple Sclerosis
  • Chandler, Arizona
  • +16 more
Jan 13, 2023

Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis

Recruiting
  • Relapsing-Remitting Multiple Sclerosis
    • Coventry, United Kingdom
    • +7 more
    May 20, 2022

    Multiple Sclerosis Trial in Newark (Betaseron, Copaxone)

    Completed
    Has Results
    • Multiple Sclerosis
    • Newark, New Jersey
      New Jersey Medical School
    Oct 18, 2021

    Quality of Life in Clinical Practice in Germany for

    Recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • Dresden, Saxony, Germany
        Universitätsklinikum Dresden, MS Ambulanz
      Apr 12, 2022

      Relapsing Remitting Multiple Sclerosis Trial in Norway (Rituximab, Ocrelizumab)

      Recruiting
      • Relapsing Remitting Multiple Sclerosis
      • Bergen, Norway
      • +10 more
      Mar 18, 2022

      MS-ResearchBiomarkerS

      Recruiting
      • Multiple Sclerosis
      • +10 more
        • Los Angeles, California
          Cedars-Sinai Medical Center
        Jan 26, 2022

        Transitioning Patients From Natalizumab to Ocrelizumab

        Completed
        • Relapsing Remitting Multiple Sclerosis
          • Livingston, New Jersey
          • +4 more
          Feb 2, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in Bordeaux (Clinical assessment, Ecological evaluation, Neuropsychological

          Active, not recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Clinical assessment
          • +4 more
          • Bordeaux, France
            CHU de Bordeaux - Service de neurologie
          Feb 2, 2022

          Multiple Sclerosis Trial in Haifa (Diagnosis, skin volatile organic compounds (VOCs))

          Completed
          • Multiple Sclerosis
          • Diagnosis, skin volatile organic compounds (VOCs)
          • Haifa, Israel
            Ariel Miller
          Dec 6, 2022

          Dimethyl Fumarate Persistence in RR-MS Patients Included in

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Dimethyl Fumarate
          • PSP
          • Agen, France
          • +80 more
          Mar 28, 2022

          Multiple Sclerosis Trial in Albuquerque (Isoxsuprine Hydrochloride, Placebo, Corticosteroid)

          Completed
          • Multiple Sclerosis
          • Isoxsuprine Hydrochloride
          • +2 more
          • Albuquerque, New Mexico
            University of New Mexico MS Specialty Clinic
          Jan 31, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in Yvoir (Multiparametric assessment)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Multiparametric assessment
          • Yvoir, Namur, Belgium
            CHU UCL Namur site Godinne
          Aug 19, 2022

          Multiple Sclerosis, Relapsing-Remitting, Magnetic Resonance Imaging, Methylprednisolone Trial in Sari (Methylprednisolone

          Enrolling by invitation
          • Multiple Sclerosis, Relapsing-Remitting
          • +2 more
          • Methylprednisolone succinate
          • Normal saline
          • Sari, Mazandaran, Iran, Islamic Republic of
            Mazandaran University of medical sciences
          Jul 30, 2021

          Imaging Interplay Between Axonal Damage and Repair in Multiple

          Recruiting
          • Multiple Sclerosis (MS)
          • +3 more
          • MRI
          • +2 more
          • Basel, Switzerland
            University Hospital Basel, Department of Neurology
          Dec 15, 2021

          VALIDATE: Factor VIII Trending for MS Relapse

          Withdrawn
          • Multiple Sclerosis
          • Blood sample collection for coagulation profile
          • Phoenix, Arizona
            Barrow Neurological Institute
          Sep 20, 2021

          Multiple Sclerosis, Relapsing-Remitting Trial in France (drug, procedure, behavioral)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
          • +4 more
          • Besançon, France
          • +3 more
          Oct 18, 2021

          Multiple Sclerosis, Relapsing-Remitting Trial in Italy (dietary supplement, drug, biological)

          Terminated
          Has Results
          • Multiple Sclerosis, Relapsing-Remitting
          • D-aspartate
          • +3 more
          • Cagliari, Italy
          • +16 more
          Feb 6, 2020

          Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Germany, United States (Tetanus, diphtheria, and acellular

          Recruiting
          • Multiple Sclerosis
          • Multiple Sclerosis, Relapsing-Remitting
          • Tetanus, diphtheria, and acellular pertussis vaccine
          • +2 more
          • Palo Alto, California
          • +47 more
          Jun 24, 2022

          Multiple Sclerosis Trial in New Haven ([18F]Florbetapir PET imaging)

          Completed
          Has Results
          • Multiple Sclerosis
          • [18F]Florbetapir PET imaging
          • New Haven, Connecticut
            Institute for Neurodegenerative Disorders
          Aug 26, 2021

          Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Ocrelizumab, Ocrelizumab Placebo, Fingolimod)

          Recruiting
          • Relapsing-Remitting Multiple Sclerosis
          • La Jolla, California
          • +66 more
          Jan 27, 2023

          Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Early Aggressive Therapy or Traditional Therapy
          • Birmingham, Alabama
          • +51 more
          Jan 23, 2023

          Multiple Sclerosis, Relapsing-Remitting, Caloric Restriction Trial in Pozzilli (Caloric restriction, Caloric restriction without

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Caloric Restriction
          • Caloric restriction
          • Caloric restriction without cow's milk and gluten
          • Pozzilli, IS, Italy
            Neuromed - Istituto Neurologico Mediterraneo Pozzilli
          Jul 26, 2022